Individualized therapy economics Market Outlook 2026–2038: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how individualized therapies change the economics of medicine. A drug built for one patient, or for a small group sharing one genetic variant, cannot be developed, priced or paid for in the way a blockbuster is, so developers, regulators and payers are working out new models.

The first proof is clinical feasibility. A base editor delivered by lipid nanoparticles was designed for an infant with severe carbamoyl phosphate synthetase 1 deficiency, who received three infusions from February to April 2025. The Children's Hospital of Philadelphia reported in February 2026 that the child has tolerated the therapy with no serious side effects, can eat more protein and needs less medication. One successful case shows that a therapy can be built and delivered for a single patient in months.

The second proof is regulatory. The Food and Drug Administration set out a plausible mechanism pathway in November 2025, and the Children's Hospital of Philadelphia describes it as reviewing all variant-specific versions of a gene editor as one drug, with positive results in as few as 5 to 10 patients supporting approval of the platform. A pathway that counts patients in single digits changes who can afford to develop a therapy.

The third factor is design. Researchers are building umbrella trials in which one study can cover, for example, seven urea cycle disorders caused by seven different genes. Pooling many variants under one platform spreads fixed cost across many patients, which is the central idea of N-of-1 economics.

The fourth factor is payment. A therapy for one person has no market large enough to recover the cost with a conventional price, so outcomes based payment, platform licences and public funding are the likely routes. In February 2026 the family and physicians visited Washington to urge sustained federal funding for pediatric research, which shows how much depends on public support.

The brief maps the models, their indicative market size and forecast, the factors behind their growth, the developments of the last 24 months, the key players and the adoption trajectory to 2038.

It is a focused 112-page decision brief for pharmaceutical and biotechnology firms, hospitals, payers, regulators and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which individualized modalities reach patients first, how platform approval and payment models are set, and who captures value as medicine moves from blockbuster to N-of-1.

Design platforms are the first layer. Gene editors, messenger RNA vaccines and antisense molecules can be tailored to a single variant while the delivery system and manufacturing process stay the same. The platform is reused and only the sequence changes.

Delivery is the second layer. Lipid nanoparticles carried the base editor to the liver of the first patient. Delivery to organs beyond the liver is the main technical limit on how many diseases can be treated.

Manufacturing is the third layer. Building a dose in weeks requires fast synthesis of guide sequences, quality testing in small batches and flexible plants. Cost per patient falls only if the process is standardised.

Evidence and regulation are the fourth layer. When a trial of hundreds of patients is impossible, evidence comes from the mechanism, the natural history of the disease, and results from a handful of patients, with real world follow up after approval.

The limits are delivery, cost and payment. Not every tissue can be reached, manufacturing is still costly for one patient, and payers have no standard way to pay for a therapy that will be used once. The decade turns on whether platform approval and pooled trials cut cost per patient.

The individualized therapy economics market, covering revenue from bespoke gene editing, personalized vaccines, patient-specific cell therapies and antisense treatments, and excluding standard gene therapies for large patient groups and diagnostics, is valued at USD 1.5–2.5 billion in 2026 and is projected to reach USD 45–75 billion by 2038, at a CAGR of 33%.

The 2026 base rests on early patient-specific products and programmes, personalized cancer vaccines in development and antisense treatments for individual variants. From that base, growth follows the number of platforms approved, the number of patients treated per platform and the price accepted per treatment.

The forecast is sensitive to regulatory pathways, delivery advances and payer models. Regionally, the United States leads on regulatory change and academic centres, Europe on cancer vaccine development and health technology assessment, and Asia-Pacific on manufacturing and rare disease programmes.

The base case assumes the plausible mechanism pathway is put into practice and the first platforms are approved by the early 2030s, giving the inflection around 2033. An accelerated case adds rapid delivery advances beyond the liver and broad payer acceptance, bringing the inflection to 2031 and lifting the 2038 value to the top of the range. A delayed case assumes a safety setback, narrow regulatory use and weak payer appetite, holding growth at the bottom of the range.

Growth drivers

• Successful first cases of bespoke gene editing.
• Regulatory pathways that accept small patient numbers.
• Platform reuse that spreads fixed cost.
• Pressure to treat rare diseases that have no therapy.

Enablers

• Lipid nanoparticle delivery.
• Umbrella trials across many variants.
• Public research funding.
• Flexible manufacturing for small batches.

Restraints and barriers

• Delivery limited to the liver for now.
• High cost per patient.
• No standard payer model.
• Long term safety unknowns.

Five converging forces will determine how fast individualized therapy economics scale.

The key players operating in individualized therapy economics include the Children's Hospital of Philadelphia, the University of Pennsylvania, Intellia Therapeutics, Inc., CRISPR Therapeutics AG, Beam Therapeutics Inc., Verve Therapeutics, Inc., Prime Medicine, Inc., Editas Medicine, Inc., Moderna, Inc., Merck & Co., Inc., BioNTech SE, Genentech, Inc., Novartis AG, Vertex Pharmaceuticals Incorporated, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., BridgeBio Pharma, Inc., Aldevron, LLC, Acuitas Therapeutics Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Lonza Group AG, Samsung Biologics Co., Ltd., Fabric Genomics, Inc., Illumina, Inc., Tempus AI, Inc., Genomics England Limited, the National Institutes of Health, the Food and Drug Administration, the European Medicines Agency, the Centers for Medicare & Medicaid Services, UnitedHealth Group Incorporated, CVS Health Corporation, Cigna Group, Elevance Health, Inc. and the National Institute for Health and Care Excellence.

The brief profiles representative players in each archetype and assesses which are positioned to lead as individualized therapy moves from academic cases to platforms.

The competitive landscape is forming around six archetypes. Academic and hospital pioneers. Gene editing platform developers. Vaccine and RNA developers. Large pharmaceutical and antisense leaders. Manufacturing, delivery and data suppliers. Payers and regulators. Competitive intensity is low in 2026 and is expected to rise as platform approvals approach through 2030.

Where value migrates.

In 2026 value sits with academic centres that design the first cases and with the suppliers of delivery and synthesis. By 2033 it moves to platform developers that win approval for pooled indications and to manufacturers that cut cost per dose. By 2038 it settles in platforms with several approved variants, in data and interpretation services and in payers with outcomes based contracts. Margins fall for custom, one-off work as platforms standardise.

The signals converge on feasibility and rules. A personalized therapy was designed and given within months, it was tolerated for a year, and the regulator set out a pathway under which results in as few as 5 to 10 patients could support a platform. Each signal moves individualized therapy from a one-off case to an approval route.

Patent and research activity reflects where the chain is weakest: delivery beyond the liver, fast guide design, small batch quality testing and long term safety monitoring. The brief therefore tracks four indicators: patients treated per platform, time from diagnosis to dose, cost per patient and number of platform approvals.

Regionally, the United States leads on regulatory change and academic centres, Europe on cancer vaccine development and health technology assessment, and Asia-Pacific on manufacturing and rare disease programmes. Liver diseases, metabolic disorders, selected cancers and neurological diseases are the first demand pools in that order.